论文部分内容阅读
目的:检测血清VEGF,SIL-2R在原发性肝癌介入治疗(TACE)前后水平变化。方法:30例临床确诊的原发性肝癌患者分别于介入术前1天、术后1天、7天、1月清晨空腹留取静脉血3ml,分离血清-70℃保存。VEGF,SIL-2R的测定采用ELISA法。结果:30例原发性肝癌患者血清VEGF水平在术前1天、术后1天、7天、1月的均值与术前比较,术后1天明显升高,差异有统计学意义(P<0.05);术后7天值明显下降,与术前及术后1天比较均有统计学意义(P<0.05);术后1月与术后7天比较升高,差异有统计学意义(P<0.05),与术前比较差异无统计学意义(P>0.05);血清SIL-2R水平术后1天与术前比较差异无统计学意义(P>0.05),术后7天与术前及术后1天比较均下降,且差异有统计学意义(P<0.05),术后1月与术后7天比较均上升差异有统计学意义(P<0.05),但明显低于术前,差异有统计学意义(P<0.05)。结论:(1)血清VEGF,SIL-2R水平在原发性肝癌介入治疗前后存在明显的动态变化。(2)血清VEGF,SIL-2R检测有望成为原发性肝癌介入治疗疗效评价指标。
Objective: To detect the changes of serum VEGF and SIL-2R levels before and after primary hepatic cancer intervention (TACE). Methods: Thirty patients with primary hepatocellular carcinoma who were diagnosed as clinically diagnosed were divided into three groups: one day before intervention, one day after operation, 7 days after operation, 3 ml of fasting venous blood in January and sera were stored at -70 ℃. The determination of VEGF and SIL-2R was performed by ELISA. Results: The serum levels of VEGF in 30 patients with primary liver cancer were significantly higher at 1 day, 1 day, 7 days and 1 month after operation than those before operation, and significantly increased at 1 day after operation (P <0.05). The value of 7 days after operation decreased significantly, compared with that before operation and 1 day after operation (P <0.05), and increased significantly at 1 month and 7 days after operation, the difference was statistically significant (P <0.05). There was no significant difference between the two groups (P> 0.05), but there was no significant difference between the two groups (P> 0.05) The difference was statistically significant (P <0.05), and the difference was statistically significant (P <0.05) between 1 month and 7 days after operation, but significantly lower than Before operation, the difference was statistically significant (P <0.05). Conclusion: (1) Serum levels of VEGF and SIL-2R have obvious dynamic changes before and after interventional therapy of primary liver cancer. (2) Serum VEGF, SIL-2R detection is expected to become the primary liver cancer interventional evaluation of efficacy.